Replies to post #6363 on Revance Therapeutics Inc (RVNC)

[alertmeipp]

750mm EV and 2.67x is damn cheap indeed given the potential growth rate and TAM.

This year they said 280mm minimum. Next year if they can grow 25%, that's 350mm + CD, say 80mm-100mm = 450mm sales. I think the market will pay at minimum 6x sales once they believe this is going to the right direction. (especially, a clear path of positive cash flow)

[10nisman]

Some other EV/sales ratios I got from finbox:
Pfizer Inc NYSE:PFE 3.4x
Healthcare SECTOR:HLTH.US 3.4x
Johnson & Johnson NYSE:JNJ 4.6x
Novartis AG ADR NYSE:NVS 4.7x
AstraZeneca PLC OTCPK:AZNC.F 4.8x
Abbott Laboratories NYSE:ABT 5.4x
Merck & Company Inc NYSE:MRK 5.8x
Amgen Inc NASDAQGS:AMGN 7.1x

Nobody should be valuing any of those companies using EV / Sales.